產(chǎn)品名稱(chēng)：SP600125 產(chǎn)品貨號(hào)：LC S-7979 產(chǎn)品規(guī)格：100 MG Novel, potent and selective JNK-1,-2, and -3 inhibitor (Ki = 0.19 µM). SP600125 is an ATP-competitive reversible inhibitor with >20-fold selectivity vs. a range of kinases and enzymes tested. In cells, SP600125 caused a dose-dependent inhibition of the phosphorylation of c-Jun, the expression of inflammatory genes IL-2, COX-2, TNF-α, IFN-γ, and blocked the activation and differentiation of primary human CD4 cell cultures. In animal studies, SP600125 inhibited bacterial lipopolysaccharide-induced expression of tumor necrosis factor-α and prevented anti-CD3-induced apoptosis of CD4+ CD8+ thymocytes. Bennett, B.L., et al. "SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase." Proc. Natl. Acad. Sci. USA 98: 13681-13686 (2001). SP600125 completely inhibited IL-1-induced accumulation of phospho-Jun and initiation of c-Jun transcription in synoviocytes. Han, Z., et al. "c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis." J. Clin. Invest. 108: 73-81 (2001). Storage: Store at or below -20 ºC. Solubility: Prepare initial stock solutions in DMSO (soluble at 65 mg/mL) for in vitro use; solubility in ethanol or water is low. Disposal: A
滬公網(wǎng)安備 31011002002623號(hào)
